Wednesday, November 14, 2018
Print Current Session:
|
|
Wednesday
SESSION 32:
MORE ON MEDICAL TREATMENTS AND NEW TECHNIQUES FOR TREATING RESISTANT HYPERTENSION; PREDICTIONS FOR THE FUTURE
Location: Grand Ballroom West, 3rd Floor
Moderators:David H. Deaton, MD, FACS / Ido Weinberg, MD, MSc |
|
SESSION 32 SCHEDULE | |
7:46 AM - 7:51 AM | Can Renal Denervation Still Be An Effective Treatment For Resistant Hypertension: Results With The Spyral-HTN Device (Medtronic) In A Sham Controlled RCT Suggest It Can: What About Other Endovascular Treatments |
Presenter(s):Horst Sievert, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
7:52 AM - 7:57 AM | The Mobius HD Intra-Arterial Implant (From Vascular Dynamics) To Stimulate Baroreceptor Activity And Lower BP (The CALM-2 Trial): How Does It Work And Results To Date |
Presenter(s):Kim J. Hodgson, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
7:58 AM - 8:03 AM | The ROX Coupler To Create An Iliac A-V Fistula And Control Resistant Hypertension: Positive Results Of The CONTROL HTN-2 Sham Controlled RCT: Will Blood Pressure Measurement With Light-Sensitive Finger Photoplethysmography Become A Reality |
Presenter(s):David H. Deaton, MD, FACS / Krishna J. Rocha-Singh, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:04 AM - 8:09 AM | DEBATE: Beta Blockers Lower The Postoperative Mortality Of Patients Undergoing Open Repair Of AAAs: What Drug Dose And Timing Should Be Used |
Presenter(s):Mahmoud B. Malas, MD, MHS Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:10 AM - 8:15 AM | DEBATE: The Evidence Supporting The Value Of Peri-Operative Beta Blockers In Lowering Morbidity Of Vascular Procedures Is Weak And They May Be Harmful: What Should We Do: Is It Just A Dosage Problem |
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:16 AM - 8:21 AM | What Is The Optimal Medical Treatment For Patients With CLTI; With PAD: How Much Will Medical Treatment Replace Invasive Interventions By 2028 |
Presenter(s):Ido Weinberg, MD, MSc / Michael R. Jaff, DO Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:22 AM - 8:28 AM | Panel Discussion |
8:28 AM - 8:33 AM | Adherence To Lipid Guidelines (Which Ones) In CLTI Patients Undergoing Open And Endo Revascularization Leads To A Decrease In Mortality And Major Adverse Limb Events (MALEs): How Low Should The LDL-C Be Pushed |
Presenter(s):Marc L. Schermerhorn, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:34 AM - 8:39 AM | Implications Of The CANTOS Trial Showing That An Anti-Inflammatory Drug (Canakinumab From Novartis) Reduces Strokes, MIs And Deaths Without Changing LDL-C Levels |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:40 AM - 8:45 AM | PCSK-9 Inhibitor (Evolocumab) Plus Statins Decreases MI, Stroke, MALE And Death More In PAD And Recent MI Patients Than Others: From A FOURIER RCT Trial Subanalysis: What LDL-C Level Should We Aim For |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:46 AM - 8:51 AM | The Best Antiplatelet And Anticoagulant Medications For Patients With Aggressive PAD: How Important Are LDL-C Levels: When Should Ezetemibe (Zetia) And PCSK-9 Inhibitors Be Added To Statins |
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:52 AM - 8:57 AM | Is There A Future For Bioresorbable Stents In The Coronary Arteries Or Elsewhere |
Presenter(s):Ron Waksman, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
8:58 AM - 9:04 AM | Panel Discussion |
END OF SESSION 32 | |
previous | next |